21;20(6)660-664. doi10.36849/JDD.5925.Two identical phase 3 trials (NCT03168321 and NCT03168334) and pooled post hoc analyses have established efficacy and safety of a polymeric tazarotene 0.045% lotion formulation in patients with moderate-to-severe acne. Presented here are post hoc analyses that further examine efficacy and safety of tazarotene 0.045% lotion by age and sex.
Patients aged ? 9 years with moderate-to-severe acne (score 3 or 4 on the Evaluator's Global Severity Score [EGSS]) were equally randomized to once-daily tazarotene 0.045% lotion or vehicle lotion for 12 weeks. Efficacy outcomes included inflammatory/noninflammatory lesion counts and treatment success (proportion of participants achieving ? 2-grade reduction from baseline in EGSS and score of 0 [clear] or 1 [almost clear]). Adolescent and adult females (n=1,013) and males (n=529) were subdivided into 3 age groups 13?19, 20?29, and ?30 years.
At week 12, large least-squares mean percent reductions in inflammatory and noninflammatory lesions were observed across all 3 tazarotene-treated age groups in males and females (range, -50.2% to -64.8%). Treatment success rates ranged from 23.6% to 38.4%. Across all efficacy assessments, significant differences between tazarotene and vehicle (P&lt;0.05) were generally observed in the younger male and female participants (13?19 and 20?29). https://www.selleckchem.com/CDK.html No notable age-related patterns were found for safety outcomes, though tazarotene-treated males of all age groups reported fewer adverse events than females.
Tazarotene 0.045% lotion is efficacious and well tolerated in female and male adolescents and adults with moderate-to-severe acne. J Drugs Dermatol. 2021;20(6)608-615. doi10.36849/JDD.6070.
Tazarotene 0.045% lotion is efficacious and well tolerated in female and male adolescents and adults with moderate-to-severe acne. J Drugs Dermatol. 2021;20(6)608-615. doi10.36849/JDD.6070.Current treatments for acne are often accompanied by undesirable side effects and contribute to antibiotic resistance. Gold and silver nanoparticles are an emerging treatment method with potentially fewer adverse effects.
To evaluate current literature discussing the various uses of gold and silver nanoparticles in the potential treatment of acne vulgaris.
A search of PubMed, EMBASE, and SCOPUS databases was conducted through April 22, 2020 to identify studies using gold or silver nanoparticles in the treatment of acne vulgaris.
16 original articles were identified in the systematic review including clinical studies, case reports, and in vitro publications. The available evidence found gold nanoparticles to be effective when combined with phototherapy to target overactive sebaceous glands and bacteria, or to mediate localized, targeted drug release. Silver nanoparticles have primarily been studied for their antibacterial properties.
This review found gold and silver nanoparticles to be a promising treatment for acne vulgaris. Further randomized controlled studies are needed to determine clinical efficacy and the role of gold and silver nanoparticles in the treatment algorithm for acne. J Drugs Dermatol. 2021;20(6)666-670. doi10.36849/JDD.5762.
This review found gold and silver nanoparticles to be a promising treatment for acne vulgaris. Further randomized controlled studies are needed to determine clinical efficacy and the role of gold and silver nanoparticles in the treatment algorithm for acne. J Drugs Dermatol. 2021;20(6)666-670. doi10.36849/JDD.5762.Our objective was to identify concerns, burden of disease, education gaps, and expectations of acne/acne scarring respondents and investigate acne/acne scarring related burden. Also, to consider perception of acne/acne scarring and additional education needs through responses from the general population.
One online survey from 1000 respondents aged 14&amp;ndash;26 years old who currently had moderate to severe acne and/or acne scarring (AcnePop) and one from 2000 nationally representative USA respondents aged &amp;ge;14 years old [general population (GenPop)].
Among the AcnePop, 26% had never consulted a healthcare professional and 36% never received a prescription for acne/acne scarring. Of those who had seen a medical professional, 72% consulted a dermatologist, 45% a primary care physician, and 23% a therapist/psychiatrist. The vast majority (94%) were dissatisfied with information they received from the healthcare provider. Topics they desired more information on included available treatment options (46%), how different skin types are affected by acne (44%), acne triggers (44%), and their acne severity (43%). Of GenPop (n=781) who had given unsolicited advice to people with acne, the most common suggestions were to see a doctor (47%), change their hygiene habits (39%), or change their diet (37%).
AcnePop are often dissatisfied with the information they receive from healthcare providers and more comprehensive information should be provided to help them understand their condition and available treatment options. J Drugs Dermatol. 2021;20(6)600-606. doi10.36849/JDD.5920.
AcnePop are often dissatisfied with the information they receive from healthcare providers and more comprehensive information should be provided to help them understand their condition and available treatment options. J Drugs Dermatol. 2021;20(6)600-606. doi10.36849/JDD.5920.Many vitiligo patients seek healthcare information online. However, the accuracy and quality of this information is unknown.
To determine the accuracy, quality, viewer engagement, and viewer experience of vitiligo videos on social media.
We searched the term &amp;ldquo;vitiligo&amp;rdquo; on YouTube. Videos were stratified based on source categories. Video accuracy was assessed using DAS and ANDI. Video quality was assessed using GQS. Viewer experience was assessed using AVA.
Sixty videos were evaluated for inclusion and exclusion criteria. We evaluated 49 videos with a total of 28.2 million views, 431,416 likes, and 61,976 comments. Of these videos, 27 (55%) were from healthcare sources, and 22 (45%) were from non-healthcare sources. When compared to videos from non-healthcare sources, videos from healthcare sources had significantly higher accuracy scores (ANDI = 3.69 &amp;plusmn; 0.16 vs 2.77 &amp;plusmn; 0.36; P=0.017 and DAS = 3.72 &amp;plusmn; 0.13 vs 3.07 &amp;plusmn; 0.28; P=0.029) but significantly fewer views (38,883 vs 1,231,947; P=0.